Navigation Links
Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients
Date:10/18/2010

the role fenretinide may play in treating our patients."

The double-masked, placebo-controlled, multicenter, Phase 2b study evaluated 246 patients with GA. Patients were randomized into three cohorts and received once-daily, oral doses of 100 mg or 300 mg of fenretinide or placebo for 24 months. Retinal lesion size was measured by color fundus photography, fundus autofluorescence and fluorescein angiography. Patients were also evaluated by contrast sensitivity, reading rate, visual acuity, optical coherence tomography, the incidence of choroidal neovascularization (CNV) and serum RBP levels. This is the largest study to date for an oral therapeutic agent for treatment of GA. Fenretinide was well tolerated with no severe drug-related adverse events and no significant effects on normal visual function.

Analysis of the lesion and RBP data at the conclusion of the two-year study showed that 43 percent of patients in the 300 mg fenretinide arm had a sustained RBP reduction of at least 60 percent throughout the trial. Those patients had a median lesion size growth of only 30 percent from baseline, compared to a median lesion size growth of about 50 percent in the placebo arm. Visual acuity loss in patients who experienced reduced lesion size growth was stabilized from 12 months to 24 months at six letters lost, while patients in the placebo arm showed progressive loss throughout the trial reaching an average loss of 11 letters at 24 months.

At the conclusion of the two-year study, the incidence of CNV in the placebo arm was 22 percent. Meanwhile, CNV incidence in patients receiving either dose of fenretinide was ~13 percent to 14 percent. The comparable therapeutic effect at both low and high doses of fenretinide suggests a mechanism of action that is not dependent upon reduction of serum RBP.

The accumulation of retinol (vitamin A)-derived toxins in the eye is believed to exacerbate lesion growth leading to progression of GA. Inflammation a
'/>"/>

SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kaiser Permanentes ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health
2. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
3. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
4. Albireo Announces Positive Results in Patients With Chronic Idiopathic Constipation From a Phase IIb trial of A3309
5. DATATRAK Awarded Three Phase III Studies
6. BiondVax Begins Phase IIa Study for Universal Flu Vaccine
7. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
8. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
9. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
11. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... Calif. , July 30, 2015  Amgen (NASDAQ: ... , partner and managing director of Warburg Pincus LLC, to ... pleased to welcome Fred Hassan and the deep, ... Amgen Board," said Robert A. Bradway , chairman and ... commitment to innovation will serve Amgen well." Mr. ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... CVS Caremark reiterated the company,s support that the U.S. ... approve biogeneric drugs under the Affordable Care Act. The ... Reid, testified before the FDA today during a public ... for biosimilar and interchangeable biological products held at the ...
... 2010 Spectros Corporation presented new clinical results ... Tissue Oximeter at the San Diego Convention Center ... presented during poster sessions entitled "Experimental Circulation: Ischemia ... the American Society of Anesthesiologists (ASA 2010) on ...
Cached Medicine Technology:CVS Caremark Reiterates Support for FDA Implementation of Approval Pathway for Biogeneric Drugs 2Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010 2
(Date:7/31/2015)... , ... July 31, 2015 , ... When the weather ... Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . It's ... process. , To commemorate introduction of this new type of sod, Super-Sod is giving ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New ... It was also the first provider of Exilis non-surgical fat reduction in New ... procedures it has attracted a large International clientele. Many patients travel to New ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 , ... ... CoolSculpting , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator ... FDA in January 2014 for treating the outer thighs. The original applicator required ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today ... media, and VIPs at the 2015 Vans US Open of Surfing, July 25 through ... can claim “no added sugar” on the market, is a natural choice given the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to an ... experts gathered to see if they could reach a consensus on the steps that ... and facelifts. Overall, the group reached 90 percent consensus on a series of steps ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... ROCHESTER, Minn., Sept. 4 Should doctors be,involved ... the,September issue of Mayo Clinic Proceedings, three anesthesiologists ... this question in a commentary and,two editorials., ... is,justifiable. Instead, the authors explore the current position ...
... first public,test of voter reaction to the healthcare deal ... Fabian Nunez, California voters,are expressing serious reservations about the ... today by the California Nurses Association. More than ... percent to,25 percent -- said they prefer "making sure ...
... A University of Virginia researcher has been awarded ... Allergy and Infectious Diseases to combat a growing international ... Center for Global Health, plans to take a unique ... growing increasingly resistant to certain antibiotics that work against ...
... tips to rid homes of common allergens, OMAHA, Neb., ... our time indoors getting bombarded by contaminants and,allergens, such as ... are built so air-tight that any air that gets in ... making your housekeeping,practices all the more important. Try to ...
... ABBOTT PARK, Ill., Sept. 4 Abbott (NYSE: ... Healthcare Conference on,Tuesday, Sept. 11, 2007. Thomas C. Freyman, ... a formal presentation on the,company at 8:30 a.m. Central ... will be accessible through,Abbott,s Investor Relations Web site at ...
... Mass., Sept. 4 The National Patient Safety,Foundation ... its,Corporate Council as an Associate Member. The Corporate ... products and services companies to,work along side NPSF ... and their families with a single convergent goal,-- ...
Cached Medicine News:Health News:Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment 2Health News:Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment 3Health News:New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8 2Health News:UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria 2Health News:Clean to Ease Allergy and Asthma Symptoms 2Health News:National Patient Safety Foundation Partners with Vocera Communications 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: